Hyperlipidemia-Pipeline Review, H2 2016

Hyperlipidemia-Pipeline Review, H2 2016


  • Products Id :- GMDHC8344IDB
  • |
  • Pages: 209
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Hyperlipidemia-Pipeline Review, H2 2016

Summary

Global Markets Direct's, Hyperlipidemia-Pipeline Review, H2 2016', provides an overview of the Hyperlipidemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hyperlipidemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperlipidemia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Hyperlipidemia

The report reviews pipeline therapeutics for Hyperlipidemia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Hyperlipidemia therapeutics and enlists all their major and minor projects

The report assesses Hyperlipidemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Hyperlipidemia

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Hyperlipidemia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hyperlipidemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Hyperlipidemia Overview 9

Therapeutics Development 10

Pipeline Products for Hyperlipidemia-Overview 10

Pipeline Products for Hyperlipidemia-Comparative Analysis 11

Hyperlipidemia-Therapeutics under Development by Companies 12

Hyperlipidemia-Therapeutics under Investigation by Universities/Institutes 16

Hyperlipidemia-Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Unknown Stage Products 20

Hyperlipidemia-Products under Development by Companies 21

Hyperlipidemia-Products under Investigation by Universities/Institutes 24

Hyperlipidemia-Companies Involved in Therapeutics Development 25

Acasti Pharma Inc. 25

Akcea Therapeutics Inc 26

Allergan Plc 27

Alnylam Pharmaceuticals, Inc. 28

Amgen Inc. 29

Arisaph Pharmaceuticals, Inc. 30

AstraZeneca Plc 31

BASF SE 32

BCWorld Pharm Co. Ltd. 33

BioRestorative Therapies, Inc. 34

Cadila Pharmaceuticals Limited 35

Cardax Pharmaceuticals, Inc. 36

Catabasis Pharmaceuticals, Inc. 37

CJ HealthCare Corp. 38

CymaBay Therapeutics, Inc. 39

Daewoong Pharmaceutical Co., Ltd. 40

Esperion Therapeutics, Inc. 41

Golden Biotechnology Corp. 42

HanAll Biopharma Co., Ltd. 43

Hanmi Pharmaceuticals, Co. Ltd. 44

Huons Co., Ltd. 45

Hyundai Pharmaceutical Co., Ltd. 46

Innovent Biologics, Inc. 47

Jeil Pharmaceutical Co., Ltd. 48

Kowa Company, Ltd. 49

Kyorin Pharmaceutical Co., Ltd. 50

LG Life Science LTD. 51

LipimetiX Development Inc 52

Matinas BioPharma Holdings, Inc. 53

Pfizer Inc. 54

Pharmena SA 55

Protalix BioTherapeutics, Inc. 56

Regeneron Pharmaceuticals Inc 57

Sancilio & Company, Inc. 58

Yuhan Corporation 59

Zydus Cadila Healthcare Limited 60

Hyperlipidemia-Therapeutics Assessment 61

Assessment by Monotherapy Products 61

Assessment by Combination Products 62

Assessment by Target 63

Assessment by Mechanism of Action 67

Assessment by Route of Administration 71

Assessment by Molecule Type 73

Drug Profiles 75

(amlodipine besylate + atorvastatin calcium + valsartan)-Drug Profile 75

(amlodipine besylate + rosuvastatin calcium + valsartan)-Drug Profile 76

(atorvastatin calcium + losartan potassium)-Drug Profile 77

(atorvastatin calcium + metformin hydrochloride) XR-Drug Profile 78

(ezetimibe + rosuvastatin calcium)-Drug Profile 79

(gemigliptin + rosuvastatin calcium)-Drug Profile 80

(metformin hydrochloride SR + rosuvastatin calcium)-Drug Profile 81

AC-261066-Drug Profile 82

AEM-28-Drug Profile 83

AEM-2802-Drug Profile 85

AEM-2814-Drug Profile 86

ALN-AC3-Drug Profile 87

ALN-ANG-Drug Profile 88

antroquinonol-Drug Profile 89

ARI-3037MO-Drug Profile 91

BCWPC-001-Drug Profile 93

bempedoic acid-Drug Profile 94

bezafibrate ER-Drug Profile 102

BH-03004-Drug Profile 103

BioE-1115-Drug Profile 104

bococizumab-Drug Profile 105

BSN-272-Drug Profile 109

CAT-2000 Series-Drug Profile 110

CAT-2003-Drug Profile 111

CDX-085-Drug Profile 114

centatin-Drug Profile 116

DWJ-1351-Drug Profile 117

etanercept biosimilar-Drug Profile 118

evolocumab-Drug Profile 120

gemcabene calcium-Drug Profile 132

HOB-071-Drug Profile 134

HU-012-Drug Profile 135

IBI-306-Drug Profile 136

icosabutate-Drug Profile 137

IMMH-007-Drug Profile 138

ISIS-APOCIIILRx-Drug Profile 139

JS-002-Drug Profile 140

K-312-Drug Profile 141

leucine + niacin-Drug Profile 142

LTPO-3FA-Drug Profile 143

MAT-9001-Drug Profile 144

MBX-8025-Drug Profile 146

MN-002-Drug Profile 149

NKPL-66-Drug Profile 150

Oligonucleotide for Hyperlipidemia and Atherosclerosis-Drug Profile 154

omega-3-carboxylic acids-Drug Profile 155

PF-06427878-Drug Profile 159

PF-06815345-Drug Profile 160

Protein to Inhibit HMG-CoA Reductase for Hyperlipidemia-Drug Profile 161

REGN-1001-Drug Profile 162

saroglitazar-Drug Profile 163

SC-401-Drug Profile 165

Small Molecule for Atherosclerosis and Hyperlipidemia-Drug Profile 166

Small Molecule for Hyperlipidemia-Drug Profile 167

Small Molecule for Hypertriglyceridaemia-Drug Profile 168

Small Molecule for Type 2 Diabetes and Hyperlipidemia-Drug Profile 169

Stem Cell Therapy for Hypertension, Hyperlipidemia, Obesity and Type 2 Diabetes-Drug Profile 170

Synthetic Peptides for Cardiovascular, Gastrointestinal, Metabolic Disorders and Infectious Disease-Drug Profile 172

TRIA-662-Drug Profile 173

volanesorsen sodium-Drug Profile 175

YH-22189-Drug Profile 181

Hyperlipidemia-Dormant Projects 182

Hyperlipidemia-Discontinued Products 191

Hyperlipidemia-Product Development Milestones 192

Featured News & Press Releases 192

Appendix 204

Methodology 204

Coverage 204

Secondary Research 204

Primary Research 204

Expert Panel Validation 204

Contact Us 204

Disclaimer 205

List of Tables

Number of Products under Development for Hyperlipidemia, H2 2016 14

Number of Products under Development for Hyperlipidemia-Comparative Analysis, H2 2016 15

Number of Products under Development by Companies, H2 2016 17

Number of Products under Development by Companies, H2 2016 (Contd..1) 18

Number of Products under Development by Companies, H2 2016 (Contd..2) 19

Number of Products under Investigation by Universities/Institutes, H2 2016 20

Comparative Analysis by Late Stage Development, H2 2016 21

Comparative Analysis by Clinical Stage Development, H2 2016 22

Comparative Analysis by Early Stage Development, H2 2016 23

Comparative Analysis by Unknown Stage Development, H2 2016 24

Products under Development by Companies, H2 2016 25

Products under Development by Companies, H2 2016 (Contd..1) 26

Products under Development by Companies, H2 2016 (Contd..2) 27

Products under Investigation by Universities/Institutes, H2 2016 28

Hyperlipidemia-Pipeline by Acasti Pharma Inc., H2 2016 29

Hyperlipidemia-Pipeline by Akcea Therapeutics Inc, H2 2016 30

Hyperlipidemia-Pipeline by Allergan Plc, H2 2016 31

Hyperlipidemia-Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016 32

Hyperlipidemia-Pipeline by Amgen Inc., H2 2016 33

Hyperlipidemia-Pipeline by Arisaph Pharmaceuticals, Inc., H2 2016 34

Hyperlipidemia-Pipeline by AstraZeneca Plc, H2 2016 35

Hyperlipidemia-Pipeline by BASF SE, H2 2016 36

Hyperlipidemia-Pipeline by BCWorld Pharm Co. Ltd., H2 2016 37

Hyperlipidemia-Pipeline by BioRestorative Therapies, Inc., H2 2016 38

Hyperlipidemia-Pipeline by Cadila Pharmaceuticals Limited, H2 2016 39

Hyperlipidemia-Pipeline by Cardax Pharmaceuticals, Inc., H2 2016 40

Hyperlipidemia-Pipeline by Catabasis Pharmaceuticals, Inc., H2 2016 41

Hyperlipidemia-Pipeline by CJ HealthCare Corp., H2 2016 42

Hyperlipidemia-Pipeline by CymaBay Therapeutics, Inc., H2 2016 43

Hyperlipidemia-Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016 44

Hyperlipidemia-Pipeline by Esperion Therapeutics, Inc., H2 2016 45

Hyperlipidemia-Pipeline by Golden Biotechnology Corp., H2 2016 46

Hyperlipidemia-Pipeline by HanAll Biopharma Co., Ltd., H2 2016 47

Hyperlipidemia-Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016 48

Hyperlipidemia-Pipeline by Huons Co., Ltd., H2 2016 49

Hyperlipidemia-Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016 50

Hyperlipidemia-Pipeline by Innovent Biologics, Inc., H2 2016 51

Hyperlipidemia-Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2016 52

Hyperlipidemia-Pipeline by Kowa Company, Ltd., H2 2016 53

Hyperlipidemia-Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016 54

Hyperlipidemia-Pipeline by LG Life Science LTD., H2 2016 55

Hyperlipidemia-Pipeline by LipimetiX Development Inc, H2 2016 56

Hyperlipidemia-Pipeline by Matinas BioPharma Holdings, Inc. , H2 2016 57

Hyperlipidemia-Pipeline by Pfizer Inc., H2 2016 58

Hyperlipidemia-Pipeline by Pharmena SA, H2 2016 59

Hyperlipidemia-Pipeline by Protalix BioTherapeutics, Inc., H2 2016 60

Hyperlipidemia-Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 61

Hyperlipidemia-Pipeline by Sancilio & Company, Inc., H2 2016 62

Hyperlipidemia-Pipeline by Yuhan Corporation, H2 2016 63

Hyperlipidemia-Pipeline by Zydus Cadila Healthcare Limited, H2 2016 64

Assessment by Monotherapy Products, H2 2016 65

Assessment by Combination Products, H2 2016 66

Number of Products by Stage and Target, H2 2016 68

Number of Products by Stage and Mechanism of Action, H2 2016 72

Number of Products by Stage and Route of Administration, H2 2016 76

Number of Products by Stage and Molecule Type, H2 2016 78

Hyperlipidemia-Dormant Projects, H2 2016 186

Hyperlipidemia-Dormant Projects (Contd..1), H2 2016 187

Hyperlipidemia-Dormant Projects (Contd..2), H2 2016 188

Hyperlipidemia-Dormant Projects (Contd..3), H2 2016 189

Hyperlipidemia-Dormant Projects (Contd..4), H2 2016 190

Hyperlipidemia-Dormant Projects (Contd..5), H2 2016 191

Hyperlipidemia-Dormant Projects (Contd..6), H2 2016 192

Hyperlipidemia-Dormant Projects (Contd..7), H2 2016 193

Hyperlipidemia-Dormant Projects (Contd..8), H2 2016 194

Hyperlipidemia-Discontinued Products, H2 2016 195

List of Figures

Number of Products under Development for Hyperlipidemia, H2 2016 14

Number of Products under Development for Hyperlipidemia-Comparative Analysis, H2 2016 15

Number of Products under Development by Companies, H2 2016 16

Number of Products under Investigation by Universities/Institutes, H2 2016 20

Comparative Analysis by Late Stage Development, H2 2016 21

Comparative Analysis by Clinical Stage Development, H2 2016 22

Comparative Analysis by Early Stage Products, H2 2016 23

Assessment by Monotherapy Products, H2 2016 65

Assessment by Combination Products, H2 2016 66

Number of Products by Top 10 Targets, H2 2016 67

Number of Products by Stage and Top 10 Targets, H2 2016 67

Number of Products by Top 10 Mechanism of Actions, H2 2016 71

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 71

Number of Products by Routes of Administration, H2 2016 75

Number of Products by Stage and Routes of Administration, H2 2016 75

Number of Products by Molecule Types, H2 2016 77

Number of Products by Stage and Molecule Types, H2 2016 77

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Acasti Pharma Inc.

Akcea Therapeutics Inc

Allergan Plc

Alnylam Pharmaceuticals, Inc.

Amgen Inc.

Arisaph Pharmaceuticals, Inc.

AstraZeneca Plc

BASF SE

BCWorld Pharm Co. Ltd.

BioRestorative Therapies, Inc.

Cadila Pharmaceuticals Limited

Cardax Pharmaceuticals, Inc.

Catabasis Pharmaceuticals, Inc.

CJ HealthCare Corp.

CymaBay Therapeutics, Inc.

Daewoong Pharmaceutical Co., Ltd.

Esperion Therapeutics, Inc.

Golden Biotechnology Corp.

HanAll Biopharma Co., Ltd.

Hanmi Pharmaceuticals, Co. Ltd.

Huons Co., Ltd.

Hyundai Pharmaceutical Co., Ltd.

Innovent Biologics, Inc.

Jeil Pharmaceutical Co., Ltd.

Kowa Company, Ltd.

Kyorin Pharmaceutical Co., Ltd.

LG Life Science LTD.

LipimetiX Development Inc

Matinas BioPharma Holdings, Inc.

Pfizer Inc.

Pharmena SA

Protalix BioTherapeutics, Inc.

Regeneron Pharmaceuticals Inc

Sancilio & Company, Inc.

Yuhan Corporation

Zydus Cadila Healthcare Limited

Hyperlipidemia Therapeutic Products under Development, Key Players in Hyperlipidemia Therapeutics, Hyperlipidemia Pipeline Overview, Hyperlipidemia Pipeline, Hyperlipidemia Pipeline Assessment

select a license
Single User License
USD 2000 INR 143800
Site License
USD 4000 INR 287600
Corporate User License
USD 6000 INR 431400

NEWSLETTER BY CATEGORY




Testimonials

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com